About hyperphosphatemia
Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.
Technavio's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.
Technavio's report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Fresenius Medical Care
• Keryx Biopharmaceuticals
• Sanofi
• Shire
• Vifor Pharma
Other prominent vendors
• Alkem
• Amgen
• Ardelyx
• AstraZeneca
• Baxter
• Bayer
• Chugai Pharmaceutical
• Japan Tobacco
• Kissei Pharmaceutical
• Kyowa Hakko Kirin
• Mylan
• Natco
• Novartis
• Opko Health
• Panion & BF Biotech
• Roxane Laboratories
• Sandoz
• Synthon
• Torri Pharmaceutical
Market driver
• Increased number of people undergoing dialysis
• For a full, detailed list, view our report
Market challenge
• Non-adherence to treatment regimens
• For a full, detailed list, view our report
Market trend
• Patient assistance programs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Product profiles
PART 05: Introduction
Key market highlights
PART 06: Disease Overview
Understanding the disease
Etiology
Effects of hyperphosphatemia
Causes
Signs and symptoms
Diagnosis
Management
Epidemiology
PART 07: Key developments in hyperphosphatemia therapy
PART 08: Guidelines for use of phosphate binders
CKD stages 2-4
CKD stage 5
PART 09: Pipeline analysis
Information on pipeline candidates
PART 10: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 11: Hyperphosphatemia management market dynamics
PART 12: Market segmentation by dosage form
Solid
Liquid
PART 13: Market segmentation by formulation
Aluminum-based phosphate binders
Calcium-based phosphate binders
Aluminum-free, calcium-free phosphate binder
Magnesium-based phosphate binders
Iron-based phosphate binders
PART 14: Geographical segmentation
Global hyperphosphatemia drugs market segmentation by geography
Hyperphosphatemia drugs market in Americas
Hyperphosphatemia drugs market in EMEA
Hyperphosphatemia drugs market in APAC
PART 15: Key leading countries
Key leading countries
Hyperphosphatemia drugs market in the US
Hyperphosphatemia drugs market in Japan
PART 16: Market drivers
PART 17: Impact of drivers
PART 18: Market challenges
PART 19: Impact of drivers and challenges
PART 20: Market trends
PART 21: Vendor landscape
Competitive scenario
Market share analysis 2014
Brand differentiation
Other prominent vendors
PART 22: Key vendor analysis
Fresenius Medical Care
Keryx Biopharmaceuticals
Sanofi
Shire
Vifor Pharma
PART 23: Appendix
List of abbreviation
PART 24: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Pathophysiology of hyperphosphatemia
Exhibit 03: Effects of hyperphosphatemia
Exhibit 04: Differential diagnosis of hyperphosphatemia
Exhibit 05: Ideal characteristics of phosphate binders
Exhibit 06: Advantages and disadvantages of different phosphate binders
Exhibit 07: Prevalence of CKD among participants by CKD stage in US 1988-2012
Exhibit 08: Number of dialysis patients worldwide 2012-2014 (millions)
Exhibit 09: Pipeline portfolio of hyperphosphatemia drugs
Exhibit 10: Global hyperphosphatemia drugs market 2014-2019 ($ millions)
Exhibit 11: Five forces analysis
Exhibit 12: Market dynamics of phosphate binders for hyperphosphatemia
Exhibit 13: Segmentation of global hyperphosphatemia drugs market by dosage form
Exhibit 14: Segmentation of global hyperphosphatemia drugs market by formulation
Exhibit 15: Global hyperphosphatemia drugs market segmentation by geography 2014
Exhibit 16: Global hyperphosphatemia drugs market segmentation by geography 2014-2019 ($ millions)
Exhibit 17: Hyperphosphatemia drugs market in Americas 2014-2019 ($ millions)
Exhibit 18: Hyperphosphatemia drugs market in EMEA 2014-2019 ($ millions)
Exhibit 19: Hyperphosphatemia drugs market in APAC 2014-2019 ($ millions)
Exhibit 20: Hyperphosphatemia drugs market in the US 2014-2019 ($ millions)
Exhibit 21: Hyperphosphatemia drugs market in Japan 2014-2019 ($ millions)
Exhibit 22: Number of individuals who underwent dialysis by region 2012-2014
Exhibit 23: Percentage of individuals who underwent dialysis by region 2012-2014
Exhibit 24: Global prevalence of diabetes 2014 and 2035 (millions)
Exhibit 25: Worldwide population aged 80 and above 1950-2050 (millions)
Exhibit 26: Impact of drivers
Exhibit 27: Rate of adherence to phosphate binders
Exhibit 28: Impact of drivers and challenges
Exhibit 29: R&D expenses by Auryxia 2012-2014 ($)
Exhibit 30: Global hyperphosphatemia market share analysis 2014
Exhibit 31: Ranking of vendors in market
Exhibit 32: Sanofi: YoY growth and revenue of Renagel and Renvela 2011-2014 ($ millions)
Exhibit 33: Sanofi: Revenue of Renagel and Renvela by region 2011-2014 ($ millions)
Exhibit 34: FOSRENOL: YoY growth and revenue of FOSRENOL except Japan 2011-2014 ($ millions)
Exhibit 35: Brand differentiation of phosphate binders by major vendors
Exhibit 36: Fresenius: Business segmentation by revenue 2014
Exhibit 37: Fresenius: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 38: Fresenius: Geographical segmentation by revenue 2014
Exhibit 39: Sanofi: Business segmentation 2014
Exhibit 40: Sanofi: Business segmentation by revenue 2014
Exhibit 41: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 42: Sanofi: Geographical segmentation by revenue 2014
Exhibit 43: Shire: Product segmentation by revenue 2014
Exhibit 44: Shire: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 45: Shire: Geographical segmentation by revenue 2014
Exhibit 46: Vifor Pharma: Product segmentation
